Chronic obstructive pulmonary disease: Official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological society; a novel phenotypic approach to COPD with patient-oriented care

Biomedical Papers

Volumn 157, Issue 2, 2013, Pages 189-201

  Koblizek, Vladimir ^a   Chlumsky, Jan ^b   Zindr, Vladimir ^c   Neumannova, Katerina ^d   Zatloukal, Jakub ^d   Zak, Jaroslav ^e   Sedlak, Vratislav ^a   Kocianova, Jana ^f   Zatloukal, Jaromir ^d   Hejduk, Karel ^g   Pracharova, Sarka ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

^c Chest Clinic   (Czech Republic)

^d PALACKÝ UNIVERSITY   (Czech Republic)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f Chest Clinic   (Czech Republic)

^g MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Clinical phenotypes; COPD; Guideline; Individualized care; Personalized medicine

Indexed keywords

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLASSIFICATION; CONSENSUS; CZECH REPUBLIC; HUMAN; MEDICAL SOCIETY; PATIENT CARE; PATIENT CARE PLANNING; PRACTICE GUIDELINE; PULMONOLOGY;

CONSENSUS; CZECH REPUBLIC; HUMANS; PATIENT CARE PLANNING; PATIENT-CENTERED CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY MEDICINE; SOCIETIES, MEDICAL;

NICOTIANA TABACUM;

EID: 84879346537     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2013.039     Document Type: Article

References (115)

1. Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, Schünemann H, Wedzicha W, MacDonald R, Shekelle P. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update for the ACP, ACCP, ATS and ERS. Ann Intern Med 2011;155(3):179-91.
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2013. 2013 Feb [cited 2013 Mar 2]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf
3. Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, Riesco JA, Trigueros JA, Piñera P, Simón A, López-Campos JL, Soriano JB, Ancochea J. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch Bronchoconeumol 2012;48(7):247-57.
4. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease (updated) Clinical guidelines CG101. 2013 Mar [cited 2013 Apr 2]. Available from: http://www.nice.org.uk/CG101
5. Celli BR. Update on the management of COPD. Chest 2008;133(6):1451-62.
6. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, Make BJ, Rabe KF, Rennard SI, Sciurba FC, Silverman EK, Vestbo J, Washko GR, Wouters EF, Martinez FJ. Chronic obstructive pulmonary disease phenotype. The future of COPD. Am J Respir Crit Care Med 2010;182(5):598-604.
7. Burgel PR, Paillasseur JL, Caillaud D, Tillie-Leblond I, Chanez P, Escamilla R, Court-Fortune I, Perez T, Carré P, Roche N. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010;36(3):531-9.
8. Gonem S, Raj V, Wardlaw J, Pavord ID, Green R, Siddiqui S. Phenotyping airways disease: an A to E approach. Clinical Et Experimental Allergy 2012;42(12):1664-83.
9. Barnes PJ. Why more research into molecular and cellular mechanisms of COPD is needed. In: Chronic Obstructive Pulmonary Disease Cellular and Molecular Mechanisms. 1st ed. Boca Raton: Taylor and Francis Group; 2005. p. 1-16.
10. Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, Hasegawa M, Shimizu K, Betsuyaku T, Ito YM, Fuke S, Igarashi T, Akiyama Y, Ogura S. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185(1):44-52.
11. Casanova C, de Torres JP, Aguirre-Jaíme A, Pinto-Plata V, Marin JM, Cordoba E, Baz R, Cote C, Celli BR. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med 2011;184(9):1015-21.
12. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, MacNee W, Miller BE, Silverman EK, Tal-Singer R, Wouters E, Rennard SI. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011;365(13):1184-92.
13. Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005;127(3):809-17.
14. O'Donnell DE, Casaburi R, Vincken W, Puente-Maestu L, Swales J, Lawrence D, Kramer B. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011;105(7):1030-6.
15. Sode B, Dahl M, Nordestgaar BG. Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish nationwide study of 7.4 million individuals. Eur Heart J 2011;32(19):2365-75.
16. de Lucas-Ramos P, Izquierdo-Alonso JL, Rodriguez-Gonzalez Moro JM, Frances JF, Lozano PV, Bellón-Cano JM. Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a casecontrol study (CONSISTE study). Int J Chron Obstr Pulmon Dis 2012 Oct 1. [Epub ahead of print] doi:10.2147/COPD.S36222
17. Lainscak M, von Haehling S, Doehner W, Sarc I, Jeric T, Ziherl K, Kosnik M, Anker SD, Suskovic S. Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. J Cachexia Sarcopenia Muscle 2011;2(2):81-6.
18. Mapel DW, Marton J. Prevalence of renal and hepatobiliary disease, laboratory abnormalities, and potentially toxic medication exposures among persons with COPD. Int J Chron Obstr Pulmon Dis 2013 Mar 15.[Epub ahead of print] doi:10.2147/COPD.S40123
19. Torres JP, Marín JM, Casanova C, Cote C, Carrizo S, Cordoba-Lanus E, Baz-Dávila R, Zulueta JJ, Aguirre-Jaime A, Saetta M, Cosio MG, Celli BR. Lung cancer in patients with chronic obstructive pulmonary disease. Incidence and predicting factors. Am J Respir Crit Care Med 2011;184(8):913-9.
20. Caballero A, Torres-Duque CA, Jaramillo C, Bolívar F, Sanabria F, Osorio P, Orduz C, Guevara DP, Maldonado D. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest 2008;133(2):343-9.
21. Miniño AM, Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2008 Natl Vital Stat Rep 2011;59(10):1-126.
22. Loddenkemper R, editor. European Lung White Book. 1st ed. Sheffield: ERSJ Ltd; 2003.
23. Atsou K, Chouaid C, Hejblum G. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. BMC Med 2011 Jan 18. [Epub] doi:10.1186/1741-7015-9-7
24. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004;364(9434):613-20.
25. Lamprecht B, Mahringer A, Soriano JB, Kaiser B, Buist AS, Studnicka M. Is spirometry properly used to diagnose COPD? Results from the BOLD study in Salzburg, Austria: a population-based analytical study. Prim Care Respir J 2013 Mar 28. [Epub ahead of print] doi:10.4104/pcrj.2013.00032
26. Maly M, Zvolsky M, Rozborilova E, Vondra V. Respiratory Mortality in Czech and Slovak Republics in the year 2011. Stud pneumol et phtiseol 2013; 73(2) in press.
27. Vondra V. Umrtnost na CHOPN v letech 1996-2005 se zdvojnasobila. Stud pneumol et phiseol 2007;73(2):75.
28. Institute of Medical Information Services. Tuberculosis and respiratory diseases 2011. 2012 Nov [cited 2013 Mar 2] Available from: http://www.uzis.cz/katalog/zdravotnicka-statistika/tuberkulozarespiracni -nemoci
29. Hooper R, Burney P, Vollmer WM, McBurnie MA, Gislason T, Tan WC, Jithoo A, Kocabas A, Welte T, Buist AS. Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project. Eur Respir J 2012;39(6):1343-53.
30. Lamprecht B, McBurnie MA, Vollmer WM, Gudmundsson G, Welte T, Nizankowska-Mogilnicka E, Studnicka M, Bateman E, Anto JM, Burney P, Mannino DM, Buist SA. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 2011;139(4):752-63.
31. Cho MH, Castaldi PJ, Wan ES, Siedlinski M, Hersh CP, Demeo DL, Himes BE, Sylvia JS, Klanderman BJ, Ziniti JP, Lange C, Litonjua AA, Sparrow D, Regan EA, Make BJ, Hokanson JE, Murray T, Hetmanski JB, Pillai SG, Kong X, Anderson WH, Tal-Singer R, Lomas DA, Coxson HO, Edwards LD, MacNee W, Vestbo J, Yates JC, Agusti A, Calverley PM, Celli BR, Crim C, Rennard S, Wouters E, Bakke P, Gulsvik A, Crapo JD, Beaty TH, Silverman EK. A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet 2012;21(4):947-57.
32. Repapi E, Sayers I, Wain LV, Burton PR, Johnson T, Obeidat M, Zhao JH, Ramasamy A, Zhai G, Vitart V, Huffman JE, Igl W, Albrecht E, Deloukas P, Henderson J, Granell R, McArdle WL, Rudnicka AR, Barroso I, Loos RJ, Wareham NJ, Mustelin L, Rantanen T, Surakka I, Imboden M, Wichmann HE, Grkovic I, Jankovic S, Zgaga L, Hartikainen AL, Peltonen L, Gyllensten U, Johansson A, Zaboli G, Campbell H, Wild SH, Wilson JF, Gläser S, Homuth G, Völzke H, Mangino M, Soranzo N, Spector TD, Polasek O, Rudan I, Wright AF, Heliövaara M, Ripatti S, Pouta A, Naluai AT, Olin AC, Torén K, Cooper MN, James AL, Palmer LJ, Hingorani AD, Wannamethee SG, Whincup PH, Smith GD, Ebrahim S, McKeever TM, Pavord ID, MacLeod AK, Morris AD, Porteous DJ, Cooper C, Dennison E, Shaheen S, Karrasch S, Schnabel E, Schulz H, Grallert H, BouatiaNaji N, Delplanque J, Froguel P, Blakey JD, Britton JR, Morris RW, Holloway JW, Lawlor DA, Hui J, Nyberg F, Jarvelin MR, Jackson C, Kähönen M, Kaprio J, Probst-Hensch NM, Koch B, Hayward C, Evans DM, Elliott P, Strachan DP, Hall IP, Tobin MD. Genome-wide association study identifies five loci associated with lung function. Nat Genet 2010;42(1):36-44.
33. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J 2005;26(5):948-68.
34. Jones P, Adamek L, Nadeau G, Banik N. Comparisons of health status scores with MRC grades in a primary care COPD population: implications for the new GOLD 2011 classification. Eur Respir J 2012 Dec 20.[Epub ahead of print] doi: 10.1183/09031936.001 25612
35. Han M, Dransfield M, Curran-Everett D, Anzueto A, Martinez F. Characteristics of GOLD 2011 grading system in the COPDGene cohort. In: European Respiratory Society Annual Congress Vienna 2012 1-5 Sep. Eur Respir J 2012; 40:Suppl.56,1646.
36. Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, Nordestgaard BG. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 2012;186(10):975-81.
37. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350(10):1005-12.
38. O'Donnell DE, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23(6):832-40.
39. Stridsman C, Lindberg A, Skär L. Fatigue in chronic obstructive pulmonary disease: a qualitative study of people's experiences. Scand J Caring Sci 2013 Mar 20.[Epub ahead of print] doi: 10.1111/scs.12033
40. Koblizek V, Tomsova M, Cermakova E, Papousek P, Pracharova S, Mandalia RA, Ceral J, Novosad J, Fila L, Sedlak V, Ruta J, Bartos V, Salajka F, Hrnciarik M. Impairment of nasal mucociliary clearance in former smokers with stable chronic obstructive pulmonary disease relates to the presence of a chronic bronchitis phenotype. Rhinology 2011;49(4):397-406.
41. Bakke PS, Rönmark E, Eagan T, Pistelli F, Annesi-Maesano I, Maly M, Meren M, Vermeire Dagger P, Vestbo J, Viegi G, Zielinski J, Lundbäck B. Recommendations for epidemiological studies on COPD. Eur Respir J 2011;38(6):1261-77.
42. Miravitlles M, Calle M, Soler-Cataluña JJ. Clinical phenotypes of COPD. Identification, definition and implications for quidelines. Arch Bronchoconeumol 2012;48(3):86-98.
43. Floto RA, Haworth CS, editors. Bronchiectasis. European Respiratory Monograph. Sheffield: European Respiratory Society; 2011.
44. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65(Suppl 1):i1-i59.
45. Aaron SD, Donaldson GC, Whitmore GA, Hurst JR, Ramsay T, Wedzicha JA. Time course and pattern of COPD exacerbation onset. Thorax 2012;67(3):238-43.
46. George C, Zermansky W, Hurst JR. Frequent exacerbations in chronic obstructive pulmonary disease. BMJ 2011 Apr 4, [Epub] doi: 10.1136/ bmj.d1434
47. Hurst JR. Exacerbation phenotyping in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011;184(6):625-6.
48. Sanchez FF, Faganello MM, Tanni SE, Lucheta PA, Pelegrino NG, Hasegawa SH, Ribeiro SM, Godoy I. Anthropometric midarm measurements can detect systemic fat-free mass depletion in patients with chronic obstructive pulmonary disease. Braz J Med Biol Res 2011;44(5):453-9.
49. Schleich FN, Seidel L, Sele J, Manise M, Quaedvlieg V, Michils A, Louis R. Exhaled nitric oxide tresholds associated with a sputum eosinophil count ≥3% in a cohort of unselected patients with asthma. Thorax 2010;65(12):1039-44.
50. Izquierdo-Alonso JL, Rodriguez-Gonzálezmoro JM, de Lucas-Ramos P, Unzueta I, Ribera X, Antón E, Martín A. Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD). Respir Med 2013;107(5):724-31.
51. Soler-Cataluña JJ, Cosío B, Izquierdo JL, López-Campos JL, Marín JM, Agüero R, Baloira A, Carrizo S, Esteban C, Galdiz JB, González MC, Miravitlles M, Monsó E, Montemayor T, Morera J, Ortega F, Peces-Barba G, Puente L, Rodríguez JM, Sala E, Sauleda J, Soriano JB, Viejo JL. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol 2012;48(9):331-7.
52. Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, van Empel VP, Bruijnzeel PL, Rutten EP, Op't Roodt J, Wouters EF, Franssen FM. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187(7):728-35.
53. Clarenbach CF, Thurnheer R, Kohler M. Vascular dysfunction in chronic obstructive pulmonary disease: current evidence and perspectives. Expert Rev Respir Med 2012;6(1):37-43.
54. Nava S, Sturani C, Hartl S, Magni G, Ciontu M, Corrado A, Simonds A. End-of-life decision making in respiratory intermediate care units: a European survey. ERS TASK FORCE. Eur Respir J 2007;30(1):156-64.
55. Lanken PN, Terry PB, Delisser HM, Fahy BF, Hansen-Flaschen J, Heffner JE, Levy M, Mularski RA, Osborne ML, Prendergast TJ, Rocker G, Sibbald WJ, Wilfond B, Yankaskas JR. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med 2008;177(8):912-27.
56. Anthoniesen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142(4):233-9.
57. Lee PN, Fry JS. Systematic review of the evidence relating FEV1 decline to giving up smoking. BMC Med 2010 Dec 14. [Epub] doi: 10.1186/1741-7015-8-84
58. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstrucBiomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013 Jun; 157(2):189-201. tive pulmonary disease (UPLIFT) a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009;374(9696):1171-8.
59. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM. Effect of pharmacotherapy on the rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178(4):332-8.
60. Jenkins CR, Jones PW, Calverley PM, Celli BR, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009 Jun 30. [Epub] doi: 10.1186/1465-9921-10-59
61. Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, Everard ML, Horvath I, Navalesi P, Voshaar T, Chrystyn H. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011;37(6):1308-31.
62. Mahler DA, D'Urzo A, Bateman ED, Ozkan SA, White T, Peckitt C, Lassen C, Kramer B. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilatation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012;67(9):781-8.
63. Tashkin DP, Fabbri LM. Long-acting beta-agonist in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010 Oct 29. [Epub] doi: 10.1186/1465-9921-11-149
64. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM. Tiotropium versus salm terol for the prevention of exacerbation of COPD. N Engl J Med 2011;364(12):1093-103.
65. Calverley PM, Anderson JA, Celli BR, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-89.
66. Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182(2):155-62.
67. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011;37(2):273-9.
68. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R. Efficacy and tolerability of budesonide/ formoterol addend to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180(8):741-50.
69. Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011 Jun 14. [Epub] doi: 10.1136/bmj.d3215
70. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium the FDA's conclusions. N Engl J Med 2010;363(12):1097-9.
71. Kesten S, Casaburi R, Kukafka D, Cooper CB. Improvement in selfreported exercise participation with combination of tiotropium and and rehabilitative exercise training in COPD patients. Int J Chron Obstr Pulmon Dis 2008;3(1):127-36.
72. Calverley PM, Stockley RA, Seemungal TA, Hagan G, Willits LR, Riley JH, Wedzicha JA. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011;139(3):505-12.
73. Ferguson GT, Calverley PM, Anderson JA, Jenkins CR, Jones PW, Willits LR, Yates JC, Vestbo J, Celli BR. Prevalence and progression of osteoporosis in patients with COPD: results from the TORCH study. Chest 2009;136(6):1456-65.
74. Hodgkin JE, Celli BR, Connors GL, editors. Pulmonary rehabilitation. Guidelines to success. 4th ed. St.Louis, Missouri: Mosby Elsevier; 2009.
75. Centers for disease control and prevention. Prevention and control of seasonal influenza vaccines. Recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR Morb Mortal Wkly Rep 2009;58:1-52.
76. Centers for disease control and prevention. Recommended adult immunization schedule. United States 2010. MMWR Morb Mortal Wkly Rep 2011;60:1-4.
77. Vila-Corcoles A, Ochoa-Gondar O. Pneumococcal vaccination among adults with chronic respiratory diseases: a historical overview. Expert Rev Vaccines 2012;1(2):221-236.
78. Ardanuy C, Marimón JM, Calatayud L, Giménez M, Alonso M, Grau I, Pallarés R, Pérez-Trallero E, Liñares J. Epidemiology of invasive pneumococcal disease in older people in Spain (2007-2009): implications for future vaccination strategies. PLos One 20127(8):e43619. [Epub ahead of print] doi: 10.1371/journal.pone.0043619
79. Stone RA, Lowe D, Potter JM, Buckingham RJ, Roberts CM, Pursey NJ. Managing patients with COPD exacerbation: does age matter? Age Ageing 2012;41(4):461-8.
80. Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, Sigmund R, Seibold W, Moroni-Zentgraf P, Bateman ED. Tiotropium in asthma poorly controlled with with standard combination therapy. N Engl J Med 2012;367(13):1198-207.
81. Thomsen M, Nordestgaard BG, Sethi AA, Tybjærg-Hansen A, Dahl M. β2-adrenergic receptor polymorphisms, asthma and COPD: two large population-based studies. Eur Respir J 2012;39(3):558-66.
82. Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, Della Cioppa G. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002;121(4):1058-69.
83. Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbröker D, Bethke TD, Hiemstra PS, Rabe KF. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007;62(12):1081-7.
84. Rabe KF. Roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Rev Resp Med 2010;4(5):543-55.
85. Wood A, Stockley R. Alpha one antitrypsin deficiency: from gene to treatment. Respiration 2007;74(5):481-92.
86. Wood A, Tan S, Stockley R. Chronic obstructive pulmonary disease: towards pharmacogenetics. Genome Med 2009;1(11):112.
87. Benditt JO. Surgical options for patients with COPD: sorting out the choices. Respir Care 2006;51(2):173-82.
88. Martinez FJ, Chang AC, Chan KM. Surgical Therapy for COPD. In: Rennard SI, Rodríguez-Roisin S, Huchon G, Roche, N, editors. Clinical Management of Chronic Obstructive Pulmonary Disease. 2nd ed. New York: Informa. Healthcare; 2008. p. 435-74.
89. Criner GJ, Cordova F, Sternberg AL, Martinez FJ. The National Emphysema Treatment Trial (NETT): Part I: Lessons learned about emphysema Am J Respir Crit Care Med 2011;184(7):763-70.
90. Criner GJ, Cordova F, Sternberg AL, Martinez FJ. The National Emphysema Treatment Trial (NETT) Part II: Lessons learned about lung volume reduction surgery. Am J Respir Crit Care Med 2011;184(8):881-93.
91. Herth FJ, Noppen M, Valipour A, Leroy S, Vergnon JM, Ficker JH, Egan JJ, Gasparini S, Agusti C, Holmes-Higgin D, Ernst A. Efficacy predictors of lung volumereduction with Zephyr valves in a Europeancohort. Eur Respir J 2012;39(6):1334-42.
92. Herth FJ, Eberhardt R, Gompelmann D, Ficker JH, Wagner M, Ek L, Schmidt B, Slebos DJ. Radiological and clinical outcomes of using Chartis™ to plan endobronchial valve treatment. Eur Respir J 2013;41(2):302-8.
93. Anker SD, John M, Pedersen PU, Raguso C, Cicoira M, Dardai E, Laviano A, Ponikowski P, Schols AM, Becker HF, Böhm M, Brunkhorst FM, Vogelmeier C. ESPEN Guidelines on Enteral Nutrition: Cardiology and pulmonology. Clin Nutr 2006;25(2):311-8.
94. Anker SD, Laviano A, Filippatos G, John M, Paccagnella A, Ponikowski P, Schols AM. ESPEN Guidelines on Parenteral Nutrition: on cardiology and pneumology. Clin Nutr 2009;28(4):455-60.
95. Elborn S, Tunney MM. Macrolide and bronchiectasis. Clinical benefit with a resistance price. JAMA 2013;309(12):1295-6.
96. Pannu KD. Azitromycin 250mg daily reduces exacerbation frequency and improves quality of life in selected COPD patients. Thorax 2012;67(5):391.
97. Peters J, Anzueto A. Azitromycin once daily for 1 year reduced acute COPD exacerbations. Ann Intern Med 2012;156(2):JC1-JC10.
98. Pomares X, Montón C, Espasa M, Casabon J, Monsó E, Gallego M. Long-term azitromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obstr Pulmon Dis 2011 Sep 6. [Epub ahead of print] doi: 10.2147/COPD.S23655
99. Albert RK, Connett J, Bailey WC. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365(8):689-98.
100. Uzun S, Djamin RS, Kluytmans J, Van't Veer NE, Ermens AA, Pelle AJ, Mulder P, van der Eerden MM, Aerts J. Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial. Trials 2012 Jun 9. [Epub ahead of print] doi: 10.1186/1745-6215-13-82
101. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, van der Werf TS, Boersma WG. Effect of azitromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis. The BAT randomized controlled trial. JAMA 2013;309(12):1251-9.
102. Sethi S, Jones PW, Theron MS, Miravitlles M, Rubinstein E, Wedzicha JA, Wilson R. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010;11(11):10.
103. Hobbs K, Brown D. Consider adding this drug to Fight COPD that's severe. J Fam Pract 2012;61(7):414-6.
104. Decramer M, Janssens W. Mucoactive therapy in COPD. Eur Respir Rev 2010;19(116):134-40.
105. Moretti M, Bottrighi P, Dallari R, Da Porto R, Dolcetti A, Grandi P, Garuti G, Guffanti E, Roversi P, De Gugliemo M, Potena A. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res 2004;30(4):143-52.
106. Czech Pneumological and Phthisiological Society. Guidelines for indication of home long term oxygen therapy 2013. 2013 Apr [cited 2013 Apr 17]. Available from: http://www.pneumologie.cz/odborne/doc/Standard%20DDOT-%20final.pdf
107. Somfay A, Porszasz J, Lee SM, Casaburi R. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J 2001;18(1):77-84.
108. Edvardsen A, Akerø A, Christensen CC, Ryg M, Skjønsberg OH. Air travel and COPD: A new algorithm for pre-flight evaluation. Thorax 2012;67(11):964-9.
109. Dreher M, Storre JH, Schmoor C, Windisch W. High intensity versus low-intensity non-invasive ventilation in patients with stable hypercapnic COPD: a randomised crossover trial. Thorax 2010;65(4):303-8.
110. Duiverman ML, Wempe JB, Bladder G, Jansen DF, Kerstjens HA, Zijlstra JG, Wijkstra PJ. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax 2008;63(12):1052-7.
111. Duiverman ML, Wempe JB, Bladder G, Vonk JM, Zijlstra JG, Kerstjens HA, Wijkstra PJ. Two-year home-based nocturnal non-invasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respir Res 2011 Aug 23. [Epub] doi: 10.1186/1465-9921-12-112
112. Au DH, Curtis JR. Providing Palliative and End-of-Life Care for Patients with COPD. In: Rennard SI, Rodríguez-Roisin S, Huchon G, Roche N, editors. Clinical Management of Chronic Obstructive Pulmonary Disease 2nd ed. New York: Informa. Healthcare; 2008. p. 515-29.
113. Kamal AH, Maguire JM, Wheeler JL, Currow DC, Abernethy AP. Dyspnea review for the palliative care professional: treatment goals and therapeutic options. J Palliat Med 2012;15(1):106-14.
114. Uronis HE, Currow DC, Abernethy AP. Palliative management of refractory dyspnea in COPD. Int J Chron Obstr Pulmon Dis 2006;1(3):289-304.
115. Nici L, ZuWallack R. An official American Thoracic Society workshop report: the Integrated Care of The COPD Patient. Proc Am Thorac Soc 2012;9(1):9-18.